{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:21:42Z","timestamp":1783052502556,"version":"3.54.6"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR300588"],"award-info":[{"award-number":["NIHR300588"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR305132"],"award-info":[{"award-number":["NIHR305132"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR301709"],"award-info":[{"award-number":["NIHR301709"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011703","name":"Yorkshire Cancer Research","doi-asserted-by":"publisher","award":["L389SS"],"award-info":[{"award-number":["L389SS"]}],"id":[{"id":"10.13039\/100011703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011715","name":"Macmillan Cancer Support","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011715","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009794","name":"Breast Cancer Now","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adjuvant endocrine therapy (AET) reduces breast cancer recurrence and mortality. However, up to three quarters of women with breast cancer do not take AET as prescribed. Existing interventions to support adherence have shown limited effectiveness and often do not target the range of barriers to appropriate AET use. We developed four intervention components targeting barriers to AET adherence: Short Message Service (SMS) messages targeting forgetfulness, an information leaflet targeting medication beliefs, a self-management website targeting side-effects, and an acceptance and commitment therapy-based guided self-help programme targeting psychological flexibility. In the preparation phase of the Multiphase Optimisation Strategy (MOST), we conducted an external pilot optimisation trial. We met predefined progression criteria regarding consent, component adherence and availability of outcome measures, and concluded progression to an optimisation randomised controlled trial (O-RCT) was warranted. Our primary aim is to optimise the intervention package to support adherence to AET in women with early-stage breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We will conduct a multi-centre, individually randomised superiority O-RCT using a 2\n                      <jats:sup>4<\/jats:sup>\n                      factorial design, with nested mixed-methods process and economic evaluations. We will randomise 512 women with early-stage breast cancer who have been prescribed AET to one of sixteen experimental conditions, operationalised as factors with two levels (on\/off). Each condition is comprised of unique combinations of the intervention components. All participants will receive usual care. Our primary outcome is self-reported medication adherence at 12 months post-randomisation. Key secondary and process outcomes include quality of life, self-efficacy, habit formation, medication beliefs, psychological flexibility and distress, completed at 4, 8 and 12 months post-randomisation. Within the process evaluation, semi-structured interviews with participants will be conducted 5 and 13 months post-randomisation, and with trial therapists following intervention delivery. Cost per incremental quality-adjusted life year will be estimated in a health economic evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Within the optimisation phase of the MOST framework, this trial, using a complex factorial design, will enable us to build a more effective, affordable, scalable and efficient intervention package to support AET adherence in women with breast cancer. This approach will advance intervention science by simultaneously testing the mechanisms through which the intervention components are operating.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>International Standard Randomised Controlled Trial Number ISRCTN17334319. Registered on 02\/02\/2024.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09765-6","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T02:04:10Z","timestamp":1778465050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising a behavioural intervention to support endocrine therapy adherence for women with breast cancer: protocol for the ROSETA optimisation factorial randomised controlled trial"],"prefix":"10.1186","volume":"27","author":[{"given":"Sophie M. C.","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"McNaught","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dowse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Wilkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei Loo","family":"Ow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Travis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbie","family":"Foy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise H.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Walwyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Howdon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Buxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally J. L.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Parbutt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Farrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Collinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1983-4470","authenticated-orcid":false,"given":"Samuel G.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"9765_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"9765_CR2","doi-asserted-by":"crossref","unstructured":"Kim J, Harper A, McCormack V, Sung H, Houssami N, Morgan E, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med. 2025;31(4):154\u20131162.","DOI":"10.1038\/s41591-025-03502-3"},{"issue":"6","key":"9765_CR3","first-page":"438","volume":"69","author":"CE Desantis","year":"2019","unstructured":"Desantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69(6):438\u201351.","journal-title":"CA Cancer J Clin"},{"issue":"9472","key":"9765_CR4","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687\u2013717.","journal-title":"Lancet"},{"issue":"9793","key":"9765_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"Early Breast Cancer Trialists Collaborative Group","year":"2011","unstructured":"Early Breast Cancer Trialists Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771\u201384.","journal-title":"Lancet"},{"issue":"10001","key":"9765_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"Early Breast Cancer Trialists Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341\u201352.","journal-title":"Lancet"},{"issue":"10","key":"9765_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/S1470-2045(21)00352-1","volume":"22","author":"L Del Mastro","year":"2021","unstructured":"Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L, et al. Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1458\u201367.","journal-title":"Lancet Oncol"},{"issue":"5","key":"9765_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2104162","volume":"385","author":"M Gnant","year":"2021","unstructured":"Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021;385(5):395\u2013405.","journal-title":"N Engl J Med"},{"issue":"27","key":"9765_CR9","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai W-Y, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120\u20138.","journal-title":"J Clin Oncol"},{"issue":"2","key":"9765_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10549-012-2114-5","volume":"134","author":"CC Murphy","year":"2012","unstructured":"Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459\u201378.","journal-title":"Breast Cancer Res Treat"},{"issue":"9324","key":"9765_CR11","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","volume":"359","author":"M Baum","year":"2002","unstructured":"Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002;359(9324):2131\u20139.","journal-title":"Lancet"},{"key":"9765_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102264","volume":"100","author":"A Inotai","year":"2021","unstructured":"Inotai A, \u00c1gh T, Maris R, Erd\u0151si D, Kov\u00e1cs S, Kal\u00f3 Z, et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev. 2021;100:102264.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"9765_CR13","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1038\/bjc.2013.116","volume":"108","author":"B Makubate","year":"2013","unstructured":"Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C. Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer. 2013;108(7):1515\u201324.","journal-title":"Br J Cancer"},{"issue":"5","key":"9765_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/bjc.2013.464","volume":"109","author":"C McCowan","year":"2013","unstructured":"McCowan C, Wang S, Thompson AM, Makubate B, Petrie DJ. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study. Br J Cancer. 2013;109(5):1172\u201380.","journal-title":"Br J Cancer"},{"issue":"28","key":"9765_CR15","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.23.00697","volume":"41","author":"EE Bright","year":"2023","unstructured":"Bright EE, Finkelstein LB, Nealis MS, Genung SR, Wrigley J, Gu HCJ, et al. A systematic review and meta-analysis of interventions to promote adjuvant endocrine therapy adherence among breast cancer survivors. J Clin Oncol. 2023;41(28):4548\u201361.","journal-title":"J Clin Oncol"},{"issue":"1","key":"9765_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-022-08243-4","volume":"22","author":"SMC Green","year":"2022","unstructured":"Green SMC, French DP, Graham CD, Hall LH, Rousseau N, Foy R, et al. Supporting adjuvant endocrine therapy adherence in women with breast cancer: the development of a complex behavioural intervention using Intervention Mapping guided by the Multiphase Optimisation Strategy. BMC Health Serv Res. 2022;22(1):1081.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"9765_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/pon.4959","volume":"28","author":"DJ Finitsis","year":"2019","unstructured":"Finitsis DJ, Vose BA, Mahalak JG, Salner AL. Interventions to promote adherence to endocrine therapy among breast cancer survivors: a meta-analysis. Psychooncology. 2019;28(2):255\u201363.","journal-title":"Psychooncology"},{"issue":"3","key":"9765_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-018-5012-7","volume":"173","author":"SP Heiney","year":"2019","unstructured":"Heiney SP, Parker PD, Felder TM, Adams SA, Omofuma OO, Hulett JM. A systematic review of interventions to improve adherence to endocrine therapy. Breast Cancer Res Treat. 2019;173(3):499\u2013510.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"9765_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.clbc.2016.03.006","volume":"16","author":"A Hurtado-De-Mendoza","year":"2016","unstructured":"Hurtado-De-Mendoza A, Cabling ML, Lobo T, Dash C, Sheppard VB. Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a\u00a0systematic literature review. Clin Breast Cancer. 2016;16(4):247\u201355.","journal-title":"Clin Breast Cancer"},{"key":"9765_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-91776-4","volume-title":"Optimization of behavioral, biobehavioral, and biomedical interventions: the multiphase optimization strategy (MOST)","author":"LM Collins","year":"2018","unstructured":"Collins LM. Optimization of behavioral, biobehavioral, and biomedical interventions: the multiphase optimization strategy (MOST). Cham Switzerland: Springer International Publishing; 2018."},{"issue":"11","key":"9765_CR21","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1093\/tbm\/ibab087","volume":"11","author":"LM Collins","year":"2021","unstructured":"Collins LM, Strayhorn JC, Vanness DJ. One view of the next decade of research on behavioral and biobehavioral approaches to cancer prevention and control: intervention optimization. Transl Behav Med. 2021;11(11):1998\u20132008.","journal-title":"Transl Behav Med"},{"key":"9765_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/abm\/kaad037","author":"SMC Green","year":"2023","unstructured":"Green SMC, Hall LH, French DP, Rousseau N, Parbutt C, Walwyn R, et al. Optimization of an information leaflet to influence medication beliefs in women with breast cancer: a randomized factorial experiment. Ann Behav Med. 2023. https:\/\/doi.org\/10.1093\/abm\/kaad037.","journal-title":"Ann Behav Med"},{"key":"9765_CR23","doi-asserted-by":"publisher","DOI":"10.2196\/38073","volume":"25","author":"SMC Green","year":"2023","unstructured":"Green SMC, French DP, Hall LH, Bartlett YK, Rousseau N, Raine E, et al. Codevelopment of a text messaging intervention to support adherence to adjuvant endocrine therapy in women with breast cancer: mixed methods approach. J Med Internet Res. 2023;25:e38073.","journal-title":"J Med Internet Res"},{"issue":"2","key":"9765_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-069971","volume":"13","author":"SG Smith","year":"2023","unstructured":"Smith SG, Green SMC, Ellison R, Foy R, Graham CD, Mason E, et al. Refining and optimising a behavioural intervention to support endocrine therapy adherence (ROSETA) in UK women with breast cancer: protocol for a pilot fractional factorial trial. BMJ Open. 2023;13(2):e069971.","journal-title":"BMJ Open"},{"key":"9765_CR25","doi-asserted-by":"crossref","unstructured":"Smith SG, Green SMC, McNaught E, Graham CD, Foy R, Ow PL, et al. Supporting endocrine therapy adherence in women with breast cancer: findings from the ROSETA pilot fractional factorial randomized trial. Ann Behav Med. 2025;59(1):kaaf003.","DOI":"10.1093\/abm\/kaaf003"},{"key":"9765_CR26","doi-asserted-by":"crossref","unstructured":"Green S, Rousseau N, Hall LH, French D, Graham C, Lloyd K, et al. Acceptability of four intervention components supporting medication adherence in women with breast cancer: a process evaluation of a fractional factorial pilot optimization trial. 2023.","DOI":"10.31219\/osf.io\/rpga9"},{"key":"9765_CR27","doi-asserted-by":"crossref","unstructured":"Green SMC, Graham CD, Collinson M, Ow PL, Hall LH, French DP, et al. Assessing multidimensional fidelity in a pilot optimization trial: a process evaluation of four intervention components supporting medication adherence in women with breast cancer. Transl Behav Med. 2024;15(1):ibae066.","DOI":"10.1093\/tbm\/ibae066"},{"issue":"26","key":"9765_CR28","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1056\/NEJMoa052258","volume":"353","author":"Breast International Group 1-98 Collaborative Group","year":"2005","unstructured":"Breast International Group 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747\u201357.","journal-title":"N Engl J Med"},{"issue":"21","key":"9765_CR29","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1001\/jama.2023.19793","volume":"330","author":"BC Kahan","year":"2023","unstructured":"Kahan BC, Hall SS, Beller EM, Birchenall M, Chan A-W, Elbourne D, et al. Reporting of factorial randomized trials. JAMA. 2023;330(21):2106.","journal-title":"JAMA"},{"key":"9765_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1687","volume":"348","author":"TC Hoffmann","year":"2014","unstructured":"Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.","journal-title":"BMJ"},{"issue":"12","key":"9765_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080633","volume":"8","author":"R Horne","year":"2013","unstructured":"Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients\u2019 adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS ONE. 2013;8(12):e80633.","journal-title":"PLoS ONE"},{"issue":"2","key":"9765_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF01173486","volume":"16","author":"H Leventhal","year":"1992","unstructured":"Leventhal H, Diefenbach M, Leventhal EA. Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res. 1992;16(2):143\u201363.","journal-title":"Cognit Ther Res"},{"issue":"6","key":"9765_CR33","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1007\/s11764-021-01114-7","volume":"16","author":"LH Hall","year":"2021","unstructured":"Hall LH, King NV, Graham CD, Green SMC, Barber A, Neal RD, et al. Strategies to self-manage side-effects of adjuvant endocrine therapy among breast cancer survivors: an umbrella review of empirical evidence and clinical guidelines. J Cancer Surviv. 2021;16(6):1296\u2013338.","journal-title":"J Cancer Surviv"},{"key":"9765_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cpr.2016.04.009","volume":"46","author":"CD Graham","year":"2016","unstructured":"Graham CD, Gouick J, Krah\u00e9 C, Gillanders D. A systematic review of the use of Acceptance and Commitment Therapy (ACT) in chronic disease and long-term conditions. Clin Psychol Rev. 2016;46:46\u201358.","journal-title":"Clin Psychol Rev"},{"issue":"1","key":"9765_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/bjhp.12579","volume":"27","author":"CD Graham","year":"2021","unstructured":"Graham CD, McCracken LM, Harrison A, Walburn J, Weinman J. Outlining an acceptance and commitment therapy approach to treatment non-adherence. Br J Health Psychol. 2021;27(1):1\u201312.","journal-title":"Br J Health Psychol"},{"issue":"10","key":"9765_CR36","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1007\/s10620-019-05621-7","volume":"64","author":"CI Voils","year":"2019","unstructured":"Voils CI, King HA, Thorpe CT, Blalock DV, Kronish IM, Reeve BB, et al. Content validity and reliability of a self-report measure of medication nonadherence in hepatitis C treatment. Dig Dis Sci. 2019;64(10):2784\u201397.","journal-title":"Dig Dis Sci"},{"issue":"10","key":"9765_CR37","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336.","journal-title":"Qual Life Res"},{"issue":"2","key":"9765_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0269216316659603","volume":"31","author":"SR Cohen","year":"2017","unstructured":"Cohen SR, Sawatzky R, Russell LB, Shahidi J, Heyland DK, Gadermann AM. Measuring the quality of life of people at the end of life: the McGill Quality of Life Questionnaire\u2013Revised. Palliat Med. 2017;31(2):120\u20139.","journal-title":"Palliat Med"},{"issue":"3","key":"9765_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1891\/106137407783095757","volume":"15","author":"J Risser","year":"2007","unstructured":"Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the Self-efficacy for Appropriate Medication Use Scale (SEAMS) in low-literacy patients with chronic disease. J Nurs Meas. 2007;15(3):203\u201319.","journal-title":"J Nurs Meas"},{"issue":"1","key":"9765_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5868-9-102","volume":"9","author":"B Gardner","year":"2012","unstructured":"Gardner B, Abraham C, Lally P, De Bruijn G-J. Towards parsimony in habit measurement: testing the convergent and predictive validity of an automaticity subscale of the Self-Report Habit Index. Int J Behav Nutr Phys Act. 2012;9(1):102.","journal-title":"Int J Behav Nutr Phys Act"},{"issue":"2","key":"9765_CR41","doi-asserted-by":"publisher","DOI":"10.1177\/2055102917740469","volume":"4","author":"J Brett","year":"2017","unstructured":"Brett J, Hulbert-Williams NJ, Fenlon D, Boulton M, Walter FM, Donnelly P, et al. Psychometric properties of the Beliefs about Medicine Questionnaire-adjuvant endocrine therapy (BMQ-AET) for women taking AETs following early-stage breast cancer. Health Psychol Open. 2017;4(2):2055102917740469.","journal-title":"Health Psychol Open"},{"issue":"4","key":"9765_CR42","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1073191116645905","volume":"25","author":"JL Rolffs","year":"2018","unstructured":"Rolffs JL, Rogge RD, Wilson KG. Disentangling components of flexibility via the Hexaflex Model: development and validation of the Multidimensional Psychological Flexibility Inventory (MPFI). Assessment. 2018;25(4):458\u201382.","journal-title":"Assessment"},{"key":"9765_CR43","doi-asserted-by":"crossref","unstructured":"Lovibond PF, Lovibond SH. The structure of negative emotional states: Comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. Behav Res Ther. 1995;33(3):335\u201343.","DOI":"10.1016\/0005-7967(94)00075-U"},{"issue":"5","key":"9765_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365\u201376.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9765_CR45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annonc.2019.10.027","volume":"31","author":"V Bjelic-Radisic","year":"2020","unstructured":"Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, et al. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45\u2730. Ann Oncol. 2020;31(2):283\u20138.","journal-title":"Ann Oncol"},{"key":"9765_CR46","unstructured":"UK Cancer Costs Questionnaire. [Available from: https:\/\/blogs.ed.ac.uk\/ukcc\/wp-content\/uploads\/sites\/190\/2019\/07\/UK-Cancer-Costs-Questionnaire-v3-0.pdf."},{"issue":"2","key":"9765_CR47","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"9765_CR48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jcbs.2019.08.008","volume":"14","author":"L O'Neill","year":"2019","unstructured":"O\u2019Neill L, Latchford G, McCracken LM, Graham CD. The development of the Acceptance and Commitment Therapy Fidelity Measure (ACT-FM): a Delphi study and field test. J Context Behav Sci. 2019;14:111\u20138.","journal-title":"J Context Behav Sci"},{"key":"9765_CR49","unstructured":"Smith SG. SWAT 178: effects of SMS pre-notification and reminders on electronic questionnaire return using a sequential multiple assignment randomised trial (SMART) design. 2021. [Available from: https:\/\/www.qub.ac.uk\/sites\/TheNorthernIrelandNetworkforTrialsMethodologyResearch\/FileStore\/Filetoupload,1425895,en.pdf."},{"key":"9765_CR50","doi-asserted-by":"crossref","unstructured":"Green SMC, Raine E, Hall LH, Collinson M, Mason E, Gillies K, et al. Developing theory-based text messages to support retention in clinical trials: a mixed methods approach. Res Methods Med Health Sci.\u00a02022;3:263208432110695.","DOI":"10.1177\/26320843211069530"},{"issue":"13","key":"9765_CR51","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"9765_CR52","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/978-3-319-72206-1_7","volume-title":"Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)","author":"LM Collins","year":"2018","unstructured":"Collins LM. The completion of the optimization phase. In: Collins LM, editor. Optimization of behavioral, biobehavioral, and biomedical interventions: the Multiphase Optimization Strategy (MOST). Cham: Springer International Publishing; 2018. p. 227\u201366."},{"key":"9765_CR53","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-3-319-72206-1_4","volume-title":"Optimization of Behavioral, Biobehavioral, and Biomedical Interventions: The Multiphase Optimization Strategy (MOST)","author":"LM Collins","year":"2018","unstructured":"Collins LM. Interactions between components and moderation of component effects. In: Collins LM, editor. Optimization of behavioral, biobehavioral, and biomedical interventions: the Multiphase Optimization Strategy (MOST). Cham: Springer International Publishing; 2018. p. 115\u201343."},{"issue":"1","key":"9765_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/tbm\/ibab137","volume":"12","author":"JC Strayhorn","year":"2022","unstructured":"Strayhorn JC, Collins LM, Brick TR, Marchese SH, Pfammatter AF, Pellegrini C, et al. Using factorial mediation analysis to better understand the effects of interventions. Transl Behav Med. 2022;12(1):137.","journal-title":"Transl Behav Med"},{"issue":"2","key":"9765_CR55","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1037\/met0000486","volume":"28","author":"K Nylund-Gibson","year":"2023","unstructured":"Nylund-Gibson K, Garber AC, Carter DB, Chan M, Arch DA, Simon O, et al. Ten frequently asked questions about latent transition analysis. Psychol Methods. 2023;28(2):284.","journal-title":"Psychol Methods"},{"key":"9765_CR56","doi-asserted-by":"crossref","unstructured":"Parker K, Cleland V, Dollman J, Gatta JD, Hatt J, Timperio A. A latent transition analysis of physical activity and screen-based sedentary behavior from adolescence to young adulthood. Int J Behav Nutr Phys Act. 2022;19(1):98.","DOI":"10.1186\/s12966-022-01339-4"},{"issue":"5","key":"9765_CR57","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1007\/s11764-022-01234-8","volume":"17","author":"C Buck","year":"2023","unstructured":"Buck C, Pini S, Lally P, Beeken RJ, Fisher A. The impact of the COVID-19 pandemic on the health behaviours of people living with and beyond breast, prostate, and colorectal cancer\u2014a qualitative study. J Cancer Surviv. 2023;17(5):1488\u201398.","journal-title":"J Cancer Surviv"},{"key":"9765_CR58","doi-asserted-by":"crossref","unstructured":"Green SMC, Rousseau N, Hall LH, French DP, Graham CD, Lloyd KE, et al. Acceptability of four intervention components supporting medication adherence in women with breast cancer: a process evaluation of a fractional factorial pilot optimization trial. Prev Sci. 2024;25:105\u20131078.","DOI":"10.1007\/s11121-024-01711-9"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09765-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09765-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:11:27Z","timestamp":1783051887000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09765-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9765"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09765-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7020477\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial has been approved by the Research Ethics Committee (23\/YH\/0250). Informed consent will be obtained from all participants in this trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"S.G.S declares consultancy fees from Lilly for participation in an advisory board. G.V. declares honoraria from Pfizer, Novartis, Eisai, Lilly. Consultancy fees for advisory boards from AstraZeneca, Roche, Novartis, Pfizer, Seagen, Eisai, Sanofi, Daiichi Sankyo, and receipt of an institutional grant from Pfizer. J.C declares honoraria for giving talks to Breast Cancer Now and Novartis. All other authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"463"}}